Clinical trial
A Multicenter Phase II Randomized Trial Of Immunotherapy Versus Chemotherapy Guided By Circulating Tumor DNA-Based Molecular Response On Patients With Metastatic NSCLC
NCT05715229 is registered in ClinicalTrials.gov with Hackensack Meridian Health as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Multicenter Phase II Randomized Trial Of Immunotherapy Versus Chemotherapy Guided By Circulating Tumor DNA-Based Molecular Response On Patients With Metastatic NSCLC
- Lead sponsor
- Hackensack Meridian Health
- Phase
- Phase 2
- Overall status
- Terminated
- Start date
- September 29, 2023
- Completion date
- August 13, 2026
- Enrollment
- 5 (actual)
- Sites
- 3
Conditions
As the registry lists them; a condition with its own page is linked.